Sustained Ketamine Effectiveness for Suicidal Ideation (SKESI)
This observational cohort study (n=128) will evaluate the sustained effectiveness of intravenous (IV) ketamine for suicidal ideation in adults experiencing a suicidal crisis due to major depressive disorder.
Details
This is a retrospective cohort using routinely collected medical records of patients who received IV ketamine infusions for suicidal crisis in the Emergency and Post-Emergency Psychiatric Department at University Hospital Montpellier.
Patients received one or more IV ketamine infusions as an add-on to depression treatment; psychometric assessments and systematic reassessments were performed twice in the month following the last infusion to monitor suicidality and clinical course.
Primary aim is to assess sustained effectiveness on suicidal ideation and behaviour in adults treated between June 2022 and March 2024 (n=128).